Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Mark R. Hancock

Hematology Oncology | Hematology | Oncology
Baylor Scott & White Health
Scott And White Clinic
1300 E Polk St, Baylor Scott And White Clini, 
Burnet, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Baylor Scott & White Health
Scott And White Clinic
1300 E Polk St, Baylor Scott And White Clini, 
Burnet, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Hancock is a Hematologist Oncology specialist and a Hematologist in Burnet, Texas. Dr. Hancock is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Neuroendocrine Tumor, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, and Prostate Cancer. Dr. Hancock is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
Bozeman Health Deaconess Hospital
Baylor Scott & White Medical Center - Marble Falls
Bozeman Health Big Sky Medical Center
Baylor Scott & White Medical Center - Round Rock
Madison Valley Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

SCOTT AND WHITE CLINIC
1300 E Polk St, Baylor Scott And White Clini, Burnet, TX 78611
Call: 512-715-6400
Other Locations
SCOTT AND WHITE CLINIC
810 W Hwy 71, Marble Falls, TX 78654
Call: 830-201-7100
BOZEMAN HEALTH BIG SKY MEDICAL CENTER LLC
334 Town Ctr Ave, Big Sky, MT 59716
Call: 406-995-6995
SCOTT AND WHITE CLINIC
1701 E Pflugerville Pkwy, Pflugerville, TX 78660
Call: 512-259-6000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


10 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Enrollment Status: Completed
Publish Date: August 21, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Docetaxel
Study Phase: Phase 3
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
View 9 Less Clinical Trials

2 Total Publications

Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 29, 2018
View All 2 Publications
Similar Doctors
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Mohammed H. Sabbagh
Oncology | Hematology | Hematology Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Mohammed H. Sabbagh
Oncology | Hematology | Hematology Oncology

American Oncology Partners PA

3201 S Austin Ave, Suite 315, 
Georgetown, TX 
 (33.4 miles away)
512-358-9428
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mohammed Sabbagh is an Oncologist and a Hematologist in Georgetown, Texas. Dr. Sabbagh is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Myelodysplastic Syndrome (MDS), Familial Wilms Tumor 2, WT1-Related Wilms Tumor Syndromes, and Wilms Tumor. Dr. Sabbagh is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Meaghan L. Dubin
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Meaghan L. Dubin
Hematology Oncology | Hematology | Oncology

Scott And White Clinic

2401 S 31st St, 
Temple, TX 
 (55.2 miles away)
254-724-2459
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Meaghan Dubin is a Hematologist Oncology specialist and a Hematologist in Temple, Texas. Dr. Dubin is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Childhood Iron Deficiency Anemia, Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Iron Deficiency Anemia. Dr. Dubin is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Alyssa G. Rieber
Hematology Oncology | Oncology | Hematology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Alyssa G. Rieber
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

506 W Windcrest St, Suite 300, 
Fredericksburg, TX 
 (52.4 miles away)
830-990-0255
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alyssa Rieber is a Hematologist Oncology specialist and an Oncologist in Fredericksburg, Texas. Dr. Rieber is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Breast Cancer, Paget Disease of the Breast, and Pleuropulmonary Blastoma. Dr. Rieber is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hancock's expertise for a condition
ConditionClose
      • Advanced
      • ALK-Positive Non-Small Cell Lung Cancer
        Dr. Hancock is
        Advanced
        . Learn about ALK-Positive Non-Small Cell Lung Cancer.
        See more ALK-Positive Non-Small Cell Lung Cancer experts
      • Chronic B-Cell Leukemia (CBCL)
        Dr. Hancock is
        Advanced
        . Learn about Chronic B-Cell Leukemia (CBCL).
        See more Chronic B-Cell Leukemia (CBCL) experts
      • Chronic Lymphocytic Leukemia (CLL)
        Dr. Hancock is
        Advanced
        . Learn about Chronic Lymphocytic Leukemia (CLL).
        See more Chronic Lymphocytic Leukemia (CLL) experts
      • Colorectal Cancer
        Dr. Hancock is
        Advanced
        . Learn about Colorectal Cancer.
        See more Colorectal Cancer experts
      • EGFR Positive Lung Cancer
        Dr. Hancock is
        Advanced
        . Learn about EGFR Positive Lung Cancer.
        See more EGFR Positive Lung Cancer experts
      • Familial Colorectal Cancer
        Dr. Hancock is
        Advanced
        . Learn about Familial Colorectal Cancer.
        See more Familial Colorectal Cancer experts
      View All 22 Advanced Conditions
      • Experienced
      • Acinic Cell Carcinoma of Salivary Glands
        Dr. Hancock is
        Experienced
        . Learn about Acinic Cell Carcinoma of Salivary Glands.
        See more Acinic Cell Carcinoma of Salivary Glands experts
      • Acute Eosinophilic Pneumonia
        Dr. Hancock is
        Experienced
        . Learn about Acute Eosinophilic Pneumonia.
        See more Acute Eosinophilic Pneumonia experts
      • Acute Mountain Sickness
        Dr. Hancock is
        Experienced
        . Learn about Acute Mountain Sickness.
        See more Acute Mountain Sickness experts
      • Acute Myeloblastic Leukemia with Maturation
        Dr. Hancock is
        Experienced
        . Learn about Acute Myeloblastic Leukemia with Maturation.
        See more Acute Myeloblastic Leukemia with Maturation experts
      • Acute Myeloblastic Leukemia without Maturation
        Dr. Hancock is
        Experienced
        . Learn about Acute Myeloblastic Leukemia without Maturation.
        See more Acute Myeloblastic Leukemia without Maturation experts
      • Acute Myeloid Leukemia (AML)
        Dr. Hancock is
        Experienced
        . Learn about Acute Myeloid Leukemia (AML).
        See more Acute Myeloid Leukemia (AML) experts
      View All 116 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2025 All Rights Reserved